Xenon Pharmaceuticals Inc. Common Shares (XENE)
XENE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/0001193125-26-076650-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XENE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | 2014 |
| SEC CIK | 0001582313 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.5M |
| Net income | -$345.9M |
| Operating income | -$373.1M |
| Net margin | -4612.1% |
| Operating margin | -4974.3% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $199.2M |
| Total assets | $633.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 514.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $82.6M cash; operating cash flow -$89.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 98,284,734 (2026-11-05); 77,275,005 a year earlier; 65,429,711 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-03-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $23.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$110.4M | -$90.3M | $82.6M | No debt tags | $0 | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $0 | -$110.7M | -$95.4M | $119.5M | No debt tags | $0 | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $0 | -$102.3M | -$88.9M | $545.9M | No debt tags | $0 | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$105.3M | -$81.5M | $199.2M | No debt tags | $7.5M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $0 | -$90.9M | -$71.8M | $104.5M | No debt tags | $7.5M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $0 | -$84.7M | -$64.2M | $135.4M | No debt tags | $7.5M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $7.5M | -$65.0M | -$61.7M | $116.7M | No debt tags | $7.5M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$65.7M | -$54.4M | $142.7M | No debt tags | $0 | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-12 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 806 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.3% |
| 1 month | +17.6% |
| 3 months | -37.0% |
| Year to date | -9.7% |
| 1 year | +1.1% |
| From 52-week high | -43.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGN | Organon & Co. Common Stock | $13.90 | 0.00% | $3.7B |
| TNGX | Tango Therapeutics Inc. | $24.17 | -5.22% | $4.1B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier